ENZO BIOCHEM INC's ticker is ENZ and the CUSIP is 294100102. A total of 115 filers reported holding ENZO BIOCHEM INC in Q3 2017. The put-call ratio across all filers is 2.04 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $37,000 | -84.4% | 13,600 | -68.7% | 0.00% | -80.0% |
| Q1 2018 | $237,000 | -32.9% | 43,400 | 0.0% | 0.02% | -21.1% |
| Q4 2017 | $353,000 | +31.7% | 43,400 | +69.5% | 0.02% | +35.7% |
| Q3 2017 | $268,000 | +10.7% | 25,600 | -11.7% | 0.01% | -6.7% |
| Q1 2017 | $242,000 | -64.4% | 29,000 | -70.4% | 0.02% | -73.2% |
| Q4 2016 | $680,000 | +5.4% | 98,000 | -22.8% | 0.06% | +7.7% |
| Q3 2016 | $645,000 | +9.0% | 126,900 | +27.9% | 0.05% | -5.5% |
| Q2 2016 | $592,000 | +180.6% | 99,200 | +113.3% | 0.06% | +161.9% |
| Q1 2016 | $211,000 | +1.0% | 46,500 | 0.0% | 0.02% | -22.2% |
| Q4 2015 | $209,000 | +221.5% | 46,500 | +109.5% | 0.03% | +200.0% |
| Q1 2015 | $65,000 | -77.5% | 22,200 | -65.9% | 0.01% | -81.6% |
| Q4 2014 | $289,000 | -27.9% | 65,100 | -16.4% | 0.05% | -18.3% |
| Q3 2014 | $401,000 | +201.5% | 77,900 | +206.7% | 0.06% | +200.0% |
| Q2 2014 | $133,000 | +26.7% | 25,400 | 0.0% | 0.02% | +25.0% |
| Q1 2014 | $105,000 | – | 25,400 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARBERT FUND ADVISORS, INC. | 5,620,681 | $20,234,000 | 30.10% |
| Evermore Global Advisors, LLC | 4,007,851 | $14,428,000 | 3.48% |
| Fondren Management LP | 355,000 | $1,278,000 | 1.06% |
| CORRADO ADVISORS, LLC | 196,309 | $707,000 | 0.64% |
| MARATHON CAPITAL MANAGEMENT | 193,580 | $697,000 | 0.28% |
| KEMPNER CAPITAL MANAGEMENT INC. | 95,476 | $344,000 | 0.23% |
| EAM Investors, LLC | 203,962 | $734,000 | 0.19% |
| Ariel Investments | 1,026,313 | $3,695,000 | 0.05% |
| HighVista Strategies LLC | 19,500 | $70,000 | 0.05% |
| Paradigm Financial Partners, LLC | 17,175 | $60,000 | 0.03% |